tldrdaily.news logo
Tag

Sglt2 Inhibitors

All articles tagged with #sglt2 inhibitors

health1 year ago

Diabetes Drug Shows Promise in Reducing Gout Medication Use

New research indicates that sodium-glucose cotransporter-2 inhibitors (SGLT2i), a class of diabetes drugs, may reduce the need for urate-lowering therapy and gout flare treatments in patients with both type 2 diabetes and gout. The study, presented at the American College of Rheumatology 2024 Annual Meeting, found a 31% lower rate of initiation of urate-lowering therapy among SGLT2i users. While not yet altering standard gout management, these findings suggest potential benefits of SGLT2i as an adjunct therapy, possibly reducing the burden of polypharmacy and disease complications.

via Medscape|
#clinical-research#diabetes#gout
health2 years ago

Promising Results in Phase III Trial of Novel Kidney Disease Drug

An experimental drug, BI 690517, has shown significant benefits in reducing albuminuria, a sign of kidney damage, in patients with chronic kidney disease. When combined with a standard-care medication, 70% of participants experienced a significant reduction in albuminuria. The drug is designed to inhibit the production of aldosterone, a hormone that accelerates kidney disease progression. The trial also utilized an SGLT2 inhibitor, empagliflozin, which has shown kidney-protective effects. The findings will inform a Phase III clinical trial with 11,000 patient-participants worldwide, potentially revolutionizing the treatment of kidney disease.

via Medical Xpress|
#albuminuria#clinical-trial#experimental-drug
health2 years ago

"Promising Weight Loss Drugs Show Potential Cardiorenal Benefits in Kidney Disease Patients"

New weight loss drugs, such as glycogen-like peptide-1 receptor antagonists (GLP-1 RAs) and sodium glucose contransporter-2 (SGLT2) inhibitors, may have cardiorenal benefits for patients with chronic kidney disease (CKD), according to a nephrology specialist. These drugs have shown potential cardioprotective effects and metabolic improvements in patients with CKD, who often have obesity and metabolic syndrome. However, there is limited safety data for these drugs in CKD patients, and further research is needed to determine their efficacy and potential risks for advanced and end-stage CKD.

via Pharmacy Times|
#cardiorenal-benefits#chronic-kidney-disease#glp-1-ras
healthcare2 years ago

"New Guidelines Released for Chronic Coronary Disease by AHA/ACC"

The American Heart Association (AHA) and the American College of Cardiology (ACC) have issued updated guidelines for managing patients with chronic coronary disease (CCD). The guidelines recommend changes in the use of beta-blockers, the inclusion of SGLT2 inhibitors and GLP-1 receptor agonists for select patients, and the use of statins as first-line therapy for lipid lowering. They also suggest shorter durations of dual antiplatelet therapy and discourage the use of nonprescription or dietary supplements. Revascularization is recommended in specific scenarios, and routine periodic testing is not recommended. The guidelines emphasize the importance of patient-centered care and shared decision-making.

via Medscape|
#beta-blockers#chronic-coronary-disease#guidelines
healthcare2 years ago

Revolutionizing Type 2 Diabetes Care in Primary Settings.

Primary care providers (PCPs) manage over 75% of patients with type 2 diabetes (T2D) in the United States. Recent updates to the American Diabetes Association's Standards of Care in Diabetes guideline require PCPs to reframe approaches to diabetes pharmacotherapy and educate patients on the importance of managing cardiorenal and metabolic risk in addition to glucose levels. SGLT2 inhibitors and GLP-1 receptor agonists are recommended first-line medications for T2D patients with heart failure and chronic kidney disease. The new paradigm of diabetes management emphasizes cardiorenal risk reduction and weight management in addition to focusing on glucose control and the prevention and management of microvascular and macrovascular complications with non–glucose lowering agents.

via Medscape|
#cardiometabolic-health#glp-1-receptor-agonists#healthcare